Abstract
This letter comments on the study by Ge et al. Serum α1-microglobulin (α1-MG) was reported to be associated with diabetic nephropathy, retinopathy, peripheral neuropathy, and left ventricular hypertrophy. The letter further highlights the need for multicenter validation and evaluation of clinical applicability to clarify the role of α1-MG in diabetes management.